Skip to content
Bharat Parenterals logo

Bharat Parenterals

BPLPHARMA NSE
₹1,888.60 down 24.30 (1.27%)
Market Cap
₹1,302 Cr

Bharat Parenterals (BPLPHARMA) share price was ₹1,912.90 at the 28 Oct 2026 close; market capitalisation ₹1,318 Cr; sector Healthcare. The share price rose 53.7% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 19.2% year on year to ₹93.7 Cr and net profit was −₹3.56 Cr, against −₹0.87 Cr a year earlier (compared with Jun 2025). Promoters held 67.20% of Bharat Parenterals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 42/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹1,912.90 +703.00 +58.10% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹1,302 Cr
EBITDA
₹25.40 Cr
Return on Equity
-8.76%
Debt to Equity
0.45
Book Value
₹467.55
EPS (TTM)
−₹22.35
52W High
₹2,277.60
52W Low
₹880.25

Price-based figures as of 29 Oct 2026, 10:45 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,767.5035.064,24,082 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,655.0087.632,56,310 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,607.8072.341,75,266 Cr9.540.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,186.70108.041,18,150 Cr22.290.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.8026.301,17,885 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.9034.681,11,755 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.1032.701,10,281 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Bharat Parenterals (this company)
₹1,888.60—1,302 Cr4.040.05%-8.76%-1.95%333 Cr-30 Cr
Median 8 companies₹1,828.0535.061,18,018 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

42 Weak
Overall score

Data confidence 93/100

Category scores

Quality Weak 44
Returns, margins, earnings quality 22% weight
Valuation Poor 33
Cheap vs sector & own history 24% weight
Growth Poor 3
Sales & profit trajectory 9% weight
Financial Health Poor 27
Solvency, leverage, coverage 9% weight
Momentum Strong 86
Trend strength, vol-adjusted 12% weight
Ownership Weak 44
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

8
  • Stock is trading at 4.02 times its book value
  • Company has low interest coverage ratio.
  • Company has a low return on equity of -0.79% over last 3 years.
  • Company might be capitalizing the interest cost
  • Earnings include an other income of Rs.9.60 Cr.
  • Company has high debtors of 159 days.
  • Promoter holding has decreased over last 3 years: -6.64%
  • Working capital days have increased from 100 days to 143 days

Technical Indicators

Oscillators

Bearish

Bearish
3
Neutral
5
Bullish
1

Overall

Bullish

Bearish
3
Neutral
5
Bullish
11

Moving Averages

Bullish

Bearish
0
Neutral
0
Bullish
10

Growth Rate

Revenue Growth
0.85% lower than 3Y

change over 1 year

Net Income Growth
-37.53% higher than 3Y

change over 1 year

Cash Flow Change
241%

change over 1 year

EBITDA Margin Change
75.43%

change over 1 year Operating margin 9.1% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
69.91
59.81
59.82
67.82
92.51
71.63
72.26
104
116
64.62
65.19
99.62
93.74
Expenses
59.46
55.49
53.21
66.82
88.02
79.29
68.62
102
102
63.79
63.45
100
85.21
Operating Profit
10.45
4.32
6.61
1
4.49
-7.66
3.64
2.23
13.78
0.83
1.74
-0.52
8.53
OPM %
14.95%
7.22%
11.05%
1.47%
4.85%
-10.69%
5.04%
2.14%
11.88%
1.28%
2.67%
-0.52%
9.1%
Other Income
2.1
2.6
1.26
2.64
2.54
4.21
2.94
1.93
1.06
3.53
1.33
3.63
1.11
Interest
0.89
0.63
0.58
1.13
2.77
2.91
3.33
3.94
3.69
3.11
2.9
2.85
2.45
Depreciation
1.58
1.75
1.82
3.87
9.03
9.01
8.76
8.52
8.6
8.56
8.46
8.63
8.69
PBT
10.08
4.54
5.47
-1.36
-4.77
-15.37
-5.51
-8.3
2.55
-7.31
-8.29
-8.37
-1.5
Tax %
30.46%
46.48%
33.46%
88.24%
85.32%
13.92%
43.01%
13.61%
133.73%
17.65%
16.77%
-2.51%
138%
Net Profit
7.01
2.43
3.64
-2.56
-8.84
-17.51
-7.88
-9.44
-0.87
-8.6
-9.67
-8.16
-3.56
EPS (₹)
13.02
6.05
6.5
-0.52
1.96
-11.5
-2.42
-6.86
11.94
-10.49
-6.37
-6.96
1.47
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
124
111
137
220
228
205
212
218
261
340
345
323
Expenses
114
105
124
191
200
179
183
198
234
337
330
313
Operating Profit
10
7
12
29
28
25
29
20
27
4
16
11
OPM %
8%
6%
9%
13%
12%
12%
14%
9%
10%
1.1%
4.6%
3.3%
Other Income
5
8
7
13
11
9
7
12
5
11
10
10
Interest
1
1
1
1
1
1
1
3
4
13
13
11
Depreciation
4
6
6
6
6
6
7
6
9
35
34
34
PBT
9
7
13
35
33
27
28
24
19
-34
-21
-25
Tax %
31%
8%
29%
39%
26%
25%
25%
33%
44%
29%
27%
—
Net Profit
6
7
9
21
24
20
21
16
11
-44
-27
-30
EPS (₹)
11.26
12.03
15.92
37.09
42.13
35.59
36.45
28.47
24.95
-18.33
-11.88
-22.35
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
3%
4%
-5%
-8%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6
6
6
6
6
6
6
6
6
7
7
Reserves
51
58
67
88
112
138
160
177
191
324
315
Borrowings
19
6
9
5
1
12
18
50
158
180
146
Other Liabilities
44
40
50
60
68
43
42
118
149
138
145
Total Liabilities
120
110
132
159
188
199
226
350
504
649
613
Fixed Assets
35
31
34
35
33
45
41
42
211
252
255
CWIP
0
0
0
1
12
0
26
99
25
31
35
Investments
0
1
1
1
0
43
11
0
0
5
6
Other Assets
85
79
98
121
142
111
148
209
268
360
317
Total Assets
120
110
132
159
188
199
226
350
504
649
613
Figures in ₹ Crores

Cash Flow

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
-2
6
20
14
24
-1
22
-5
-27
38
Investing
0
-2
-8
-9
-13
-43
-7
-78
-105
-137
9
Financing
0
-8
4
-4
-3
10
9
61
110
156
-47
Net Cash Flow
0
-11
2
7
-1
-8
2
4
1
-8
1
Free Cash Flow
0
-4
-2
12
0
24
-40
-68
-108
-56
-1
CFO/OP
0
-8
73
107
87
123
16
150
18
-444
305
Figures in ₹ Crores

Ratios

Particulars Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
130
143
157
106
127
121
126
188
198
184
159
Inventory Days
62
70
60
59
71
61
56
100
142
132
162
Days Payable
171
168
110
83
104
71
64
136
137
136
122
Cash Conversion Cycle
21
45
107
82
93
111
118
152
202
180
199
Working Capital Days
8
64
78
73
89
106
148
91
81
76
143
ROCE %
—
11%
18%
39%
31%
20%
17%
11%
7%
-4%
-2%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bharat Parenterals insights

67 extracted metrics + investor summaries across FY01–FY27.

Shareholding Pattern

FIIs0.11%Promot.67.20%DIIs1.29%Others12.28%Public19.12%As ofSep 2026

Documents

Frequently Asked Questions about Bharat Parenterals

What does Bharat Parenterals Ltd do?
Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations[1]
Where is Bharat Parenterals Ltd (BPLPHARMA) listed?
Bharat Parenterals Ltd trades as BPLPHARMA on the NSE and under code 541096 on the BSE.
Which sector does Bharat Parenterals Ltd belong to?
Bharat Parenterals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Bharat Parenterals Ltd?
Bharat Parenterals Ltd has a market capitalisation of ₹1,302 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Bharat Parenterals Ltd?
Over the last 52 weeks Bharat Parenterals Ltd has traded between ₹880.25 and ₹2,277.6 as of 29 Oct 2026.
Does Bharat Parenterals Ltd pay dividends?
Bharat Parenterals Ltd has a dividend yield of 0.05%.
What is the Return on Equity (ROE) of Bharat Parenterals Ltd?
Bharat Parenterals Ltd reported a return on equity of -8.76%. Its debt-to-equity ratio is 0.45.

Company Information

Incorporated in 1992, Bharat Parenterals Ltd is in the business of manufacturing and marketing of formulations[1]

Website bplindia.in
CEO Mr. Bharatkumar Rameshchandra Desai
Employees 393
Listed 2018-03-21
Face Value ₹ 10
Shares Outstanding 68,91,963

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/541096.md for Bharat Parenterals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month